Saturday, March 21, 2020 8:32:57 PM
HERTFORDSHIRE, England and PITTSBURGH, March 19, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational expertise towards identifying additional ways we may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.
For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus[1]. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed.
Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that we currently have available, will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance
Recent VTRS News
- Viatris to Participate in the BofA Securities 2024 Health Care Conference • PR Newswire (US) • 05/02/2024 09:00:00 PM
- Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health • PR Newswire (US) • 05/01/2024 10:59:00 AM
- Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 • PR Newswire (US) • 04/16/2024 08:30:00 PM
- Viatris Appoints Corinne Le Goff as Chief Commercial Officer • PR Newswire (US) • 04/15/2024 12:00:00 PM
- Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada • PR Newswire (Canada) • 04/15/2024 10:59:00 AM
- Viatris annonce le lancement de la première version générique bioéquivalente du Copaxone [MD] 20 mg/mL au Canada • PR Newswire (Canada) • 04/15/2024 10:59:00 AM
- Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States • PR Newswire (US) • 04/01/2024 10:59:00 AM
- Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline • PR Newswire (US) • 03/27/2024 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:29:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:24:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:09:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:54:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:47:44 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:26:09 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:11:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:39:17 PM
- Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance • PR Newswire (US) • 02/28/2024 11:30:00 AM
- Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration • PR Newswire (US) • 02/28/2024 06:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:00:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 10:18:00 PM
- Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results • PR Newswire (US) • 02/05/2024 11:59:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/30/2024 09:40:59 PM
- Viatris recognised as a Top Employer 2024 in the UK for the second consecutive year • PR Newswire (US) • 01/19/2024 11:56:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 11:00:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM